Cidara Therapeutics Inc. (CDTX)
21.83
0.25 (1.16%)
At close: Mar 28, 2025, 11:44 AM
1.16% (1D)
| Bid | 21.51 |
| Market Cap | 239.11M |
| Revenue (ttm) | 14.91M |
| Net Income (ttm) | -285.03M |
| EPS (ttm) | -26.82 |
| PE Ratio (ttm) | -0.81 |
| Forward PE | -2.21 |
| Analyst | Buy |
| Ask | 21.88 |
| Volume | 9,140 |
| Avg. Volume (20D) | 126,675 |
| Open | 21.81 |
| Previous Close | 21.58 |
| Day's Range | 21.50 - 21.83 |
| 52-Week Range | 10.00 - 28.42 |
| Beta | 0.88 |
About CDTX
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 15, 2015
Employees 38
Stock Exchange NASDAQ
Ticker Symbol CDTX
Website https://www.cidara.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 60.33% from the latest price.
Stock Forecasts4 months ago
+15.41%
Cidara Therapeutics shares are trading higher. The...
Unlock content with
Pro Subscription
11 months ago
+5.78%
Cidara Therapeutics shares are trading higher after the company announced the divestiture of rezafungin to Mundipharma, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing.
